MED SOC AD Adam Blum · CancerBot HealthKey.AI Acquires CancerBot: What It Means for CancerBot Users What the HealthKey Acquisition Means for CancerBot Patients and Researchers
MED SOC AD Adam Blum · CancerBot Dear Skeptical Oncologist: We Need to Talk A point-by-point response to the objections we hear from clinicians — with evidence, logic, and the occasional raised eyebrow
MED SOC TCH AD Adam Blum · CancerBot EXACT: An Open-Source Precision Clinical Trial Matcher Built on OMOP Matching a cancer patient to a clinical trial sounds like it ought to be a solved problem. In reality, most matching systems are either (a)…
AD Adam Blum · CancerBot CTOMOP: Extending OMOP to Be Comprehensive Transactional and Longitudinal Patient Record We have discussed earlier a vision for centralized patient database repositories. One of the many use cases for a truly comprehensive…
MED SOC AD Adam Blum · CancerBot ctDNA Trials in Breast Cancer: How TREAT ctDNA, DARE and Apollo Are Changing Early Intervention And Why CancerBot’s Precision Trial Matching Is Becoming Even More Important Than Ever
MED SOC AD Adam Blum · CancerBot SYMPHONY-1: Can Adding Tazemetostat to R² Improve Outcomes in Relapsed Follicular Lymphoma? Clinical trials are the engine driving innovation in cancer care — especially in diseases like follicular lymphoma (FL) where cures are…
MED SOC LIF AD Adam Blum · CancerBot CAMBRIA-1: Exploring Extended Camizestrant in Early ER+/HER2- Breast Cancer Finding the right treatment pathway after standard therapy can be complex — especially when deciding if extended adjuvant therapy might…
MED SOC AD Adam Blum · CancerBot Why Bispecific Antibodies Plus CELMoDs Could Be a Powerful New Strategy in B-Cell Lymphoma Inside Trial NCT05169515 — and why precision matching matters
MED SOC AD Adam Blum · CancerBot How T Cells Work And How New Trispecific Antibodies May Transform Multiple Myeloma Treatment
MED SOC AD Adam Blum · CancerBot Towards a Common Patient Information Schema What a unified, patient-centric data model could look like for breast cancer trial matching
MED SOC AI SCI AD Adam Blum · CancerBot Generations of Clinical Trial Matching Medical science is being drastically impeded by the lack of patient uptake of trials: a world-wide average of just 3% of patients…
MED SOC AD Adam Blum · CancerBot A Vision for Centralized Patient Data Repositories Empowering patients, enabling clinicians, and unlocking the full potential of healthcare data.
MED SOC AD Adam Blum · CancerBot Patient Data Access in My Own Cancer Journey I am heading out to a private conference on patient data access (that is apparently embargoed until conference close!). In preparation, I…
MED SOC AD Adam Blum · CancerBot BEGIN: A Manifesto for Better Patient-Centered Precision Clinical Trial Matching I discussed my personal journey with cancer here a few months ago. I tried all commercial patient-accessible clinical trial matching…
MED SOC AD Adam Blum · CancerBot What Makes a Trial Good for a Patient? CancerBot’s Trial Goodness Scoring Rubrics
MED SOC AD Adam Blum · CancerBot Accuracy of Precision Clinical Trial Matching with Follicular Lymphoma Trials on CancerBot In our last post, we discussed how clinical trial matching systems should evaluate their accuracy. Using the recommended techniques there…